Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland.
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland.
N Biotechnol. 2019 Sep 25;52:42-53. doi: 10.1016/j.nbt.2019.04.002. Epub 2019 Apr 13.
Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte infiltration at the site of disease. In this review, we present a survey of immunocytokines that have been used in preclinical models of cancer and in clinical trials. In particular, we highlight how antibody format, choice of target antigen and cytokine engineering, as well as combination strategies, may have a profound impact on therapeutic performance. Moreover, by using anti-inflammatory cytokines, antibody fusion strategies can conveniently be employed for the treatment of auto-immune and chronic inflammatory conditions.
抗体-细胞因子融合蛋白是一类新型的生物制药，具有提高细胞因子“有效载荷”治疗指数和促进疾病部位白细胞浸润的潜力。在这篇综述中，我们介绍了已在癌症临床前模型和临床试验中使用的免疫细胞因子。特别是，我们强调了抗体形式、靶抗原选择和细胞因子工程以及组合策略如何对治疗效果产生深远影响。此外，通过使用抗炎细胞因子，抗体融合策略可方便地用于治疗自身免疫和慢性炎症性疾病。
